The mechanisms of drug-resistance to IM of CML include BCR-ABL dependent (gene mutations and gene amplification) and BCR-ABL independent pathways (PI3K-AKT, P27, STAT, ERK1/2 etc.)22,28. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.